Aug 18 (Reuters) - Catalyst Pharmaceuticals Inc CPRX.O :
* CATALYST PHARMACEUTICALS AND KYE PHARMACEUTICALS ANNOUNCE AGREEMENT TO MAKE FIRDAPSE® (AMIFAMPRIDINE PHOSPHATE) AVAILABLE TO LEMS PATIENTS IN CANADA
* CATALYST PHARMACEUTICALS - KYE WILL BE RESPONSIBLE FOR ONGOING MAINTENANCE OF REGULATORY FILE AND FUTURE COMMUNICATIONS WITH HEALTH CANADA
* CATALYST PHARMACEUTICALS INC - UNDER TERMS, CO WILL SUPPLY FIRDAPSE TO KYE
* CATALYST PHARMA - UNDER TERMS, KYE TO BE RESPONSIBLE FOR PROMOTION, SALES, ADVERTISEMENT, MARKETING, PRODUCT IMPORTATION & DISTRIBUTION OF FIRDAPSE